SonaCare Medical Announces Significant Publication of Focal Therapy Comparison to Radical Therapy
January 28, 2021
CHARLOTTE, NC, UNITED STATES, January 28, 2021 /EINPresswire.com/ — SonaCare Medical, LLC, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to report the publication of Focal Therapy Compared to Radical Prostatectomy for Non-Metastatic Prostate Cancer: A Propensity Score-Matched Study(1) just released in Nature. In this analysis, focal therapy and radical prostatectomy were compared using 1-to-1 propensity score-matched for treatment year, age, PSA, Gleason, T-Stage, cancer core length and neoadjuvant hormone use. At 3, 5 and 8 years Failure Free Survival (FFS) for radical prostatectomy was 86%, 82% and 79% compared to 91%, 86% and 83% FFS for focal therapy at the same time intervals. Also, of note the secondary treatment rates were approximately 16% for radical prostatectomy and approximately 17% for focal therapy.